Immune booster combined with checkpoint blocker improves survival in metastatic melanoma
Wednesday, November 5, 2014 - 04:05
in Health & Medicine
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer if they simultaneously received an immune stimulant.